RUA Life Sciences First Half 2025 Earnings: EPS: UK£0.01 (vs UK£0.046 loss in 1H 2024)

RUA Life Sciences (LON:RUA) First Half 2025 Results

Key Financial Results

• Revenue: UK£1.52m (up 92% from 1H 2024).
• Net income: UK£636.0k (up from UK£1.01m loss in 1H 2024).
• Profit margin: 42% (up from net loss in 1H 2024). The move to profitability was primarily driven by higher revenue.
• EPS: UK£0.01 (up from UK£0.046 loss in 1H 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

RUA Life Sciences Earnings Insights

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in the United Kingdom.

Performance of the British Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for RUA Life Sciences (3 shouldn't be ignored!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.